![](/images/graphics-bg.png)
Eltrombopag in Good’s Syndrome
Joint Authors
Kristiansen, Håvard Anton
Spetalen, Signe
Heldal, Dag
Fløisand, Yngvar
Source
Issue
Vol. 2014, Issue 2014 (31 Dec. 2014), pp.1-3, 3 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2014-10-19
Country of Publication
Egypt
No. of Pages
3
Main Subjects
Abstract EN
Good’s syndrome is a rare acquired immunodeficiency associated with thymoma.
Eltrombopag is a thrombopoietin receptor agonist and has been shown to be a valuable supplement to the treatment of several types of refractory cytopenias.
In this paper, we describe a male patient suffering from Good’s syndrome with immune-mediated T-cell driven pancytopenia and absence of megakaryopoiesis.
He was successfully treated with eltrombopag resulting in a multilineage clinical response.
American Psychological Association (APA)
Kristiansen, Håvard Anton& Spetalen, Signe& Fløisand, Yngvar& Heldal, Dag. 2014. Eltrombopag in Good’s Syndrome. Case Reports in Hematology،Vol. 2014, no. 2014, pp.1-3.
https://search.emarefa.net/detail/BIM-1034742
Modern Language Association (MLA)
Kristiansen, Håvard Anton…[et al.]. Eltrombopag in Good’s Syndrome. Case Reports in Hematology No. 2014 (2014), pp.1-3.
https://search.emarefa.net/detail/BIM-1034742
American Medical Association (AMA)
Kristiansen, Håvard Anton& Spetalen, Signe& Fløisand, Yngvar& Heldal, Dag. Eltrombopag in Good’s Syndrome. Case Reports in Hematology. 2014. Vol. 2014, no. 2014, pp.1-3.
https://search.emarefa.net/detail/BIM-1034742
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1034742